ATE434035T1 - Lebender influenza impfstoff und verfahren zu seiner herstellung - Google Patents

Lebender influenza impfstoff und verfahren zu seiner herstellung

Info

Publication number
ATE434035T1
ATE434035T1 AT01985267T AT01985267T ATE434035T1 AT E434035 T1 ATE434035 T1 AT E434035T1 AT 01985267 T AT01985267 T AT 01985267T AT 01985267 T AT01985267 T AT 01985267T AT E434035 T1 ATE434035 T1 AT E434035T1
Authority
AT
Austria
Prior art keywords
cell culture
production
viruses
virus
influenza vaccine
Prior art date
Application number
AT01985267T
Other languages
English (en)
Inventor
Hermann Katinger
Andre Egorov
Boris Ferko
Julia Romanova
Dietmar Katinger
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Application granted granted Critical
Publication of ATE434035T1 publication Critical patent/ATE434035T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01985267T 2000-09-25 2001-09-25 Lebender influenza impfstoff und verfahren zu seiner herstellung ATE434035T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00120896 2000-09-25
PCT/EP2001/011087 WO2002024876A2 (en) 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture

Publications (1)

Publication Number Publication Date
ATE434035T1 true ATE434035T1 (de) 2009-07-15

Family

ID=8169944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01985267T ATE434035T1 (de) 2000-09-25 2001-09-25 Lebender influenza impfstoff und verfahren zu seiner herstellung

Country Status (12)

Country Link
US (1) US7494659B2 (de)
EP (1) EP1358319B1 (de)
JP (1) JP5063852B2 (de)
KR (2) KR20030061810A (de)
CN (1) CN1582333B (de)
AT (1) ATE434035T1 (de)
AU (2) AU2002223560B2 (de)
CA (1) CA2423038C (de)
DE (1) DE60139026D1 (de)
DK (1) DK1358319T3 (de)
ES (1) ES2327103T3 (de)
WO (1) WO2002024876A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
WO2004060278A2 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
AU2003205169A1 (en) * 2002-01-15 2003-07-30 Acambis, Inc. Viral vaccine production method
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
EP2287288B1 (de) 2002-07-09 2012-11-07 Baxter International Inc. Tierproteinfreies Zellkulturmedium
ES2305514T5 (es) * 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP2481819A1 (de) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Querstromfiltration in der Herstellung von stabilisierten Influenza-Impfstoff-Zusammensetzungen
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CA2503774C (en) 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8242254B2 (en) 2003-09-11 2012-08-14 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
ES2641832T3 (es) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Espectrometría de masas con filtración de iones selectiva por establecimiento de umbrales digitales
JP4980895B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
DK2497492T3 (en) 2004-06-01 2018-11-26 Icahn School Med Mount Sinai Genetically modified swine influenza virus and its applications
WO2006033691A2 (en) * 2004-07-02 2006-03-30 Niman Henry L Copy choice recombination and uses thereof
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
WO2006135400A2 (en) 2004-08-24 2006-12-21 Isis Pharmaceuticals, Inc. Methods for rapid identification of recombinant organisms
AU2011221414B2 (en) * 2004-10-29 2012-09-20 Takeda Pharmaceutical Company Limited Animal Protein-Free Media for Cultivation of Cells
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US20060205040A1 (en) 2005-03-03 2006-09-14 Rangarajan Sampath Compositions for use in identification of adventitious viruses
EP2471552B1 (de) 2005-03-08 2015-05-06 MedImmune, LLC Reassortierte Influenza-Viren
CA2611954C (en) * 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
JP2009502137A (ja) 2005-07-21 2009-01-29 アイシス ファーマシューティカルズ インコーポレイティッド 核酸変種の迅速な同定および定量のための方法
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
JP2009515509A (ja) * 2005-10-17 2009-04-16 アイシス ファーマシューティカルズ インコーポレイティッド インフルエンザウイルスの同定に使用する組成物
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
MX2008014391A (es) * 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CN104140958A (zh) * 2006-08-09 2014-11-12 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
EP1911836A1 (de) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Mediumzusatz für die Virusproduktion
EP2126132B1 (de) 2007-02-23 2013-03-20 Ibis Biosciences, Inc. Verfahren für schnelle forensische dna-analyse
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
EP2674486A1 (de) * 2007-06-18 2013-12-18 MedImmune, LLC Influenza-B-Viren mit Veränderungen im Hämagglutininpolypeptid
CA2692478A1 (en) * 2007-07-03 2009-01-08 Kyorin Pharmaceutical Co., Ltd. Treatment of influenza
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
RU2523587C2 (ru) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
WO2010033625A1 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2396803A4 (de) 2009-02-12 2016-10-26 Ibis Biosciences Inc Ionisationssondenanordnungen
SG173642A1 (en) 2009-02-12 2011-09-29 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CA2709340A1 (en) * 2009-07-10 2011-01-10 University Of Ottawa Mutations in the influenza a virus ns1 gene and use thereof
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
EP2454000A4 (de) 2009-07-17 2016-08-10 Ibis Biosciences Inc Systeme zur identifizierung von biowirkstoffen
EP2488656B1 (de) 2009-10-15 2015-06-03 Ibis Biosciences, Inc. Mehrfache verschiebungsverstärkung
RU2420314C1 (ru) * 2009-12-02 2011-06-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Способ получения живой культуральной вакцины против вируса гриппа
CA2801151A1 (en) * 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
EP2646051A4 (de) 2010-12-02 2014-05-28 Oncolytics Biotech Inc Flüssige virale formulierungen
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (de) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Verfahren und zusammensetzungen für therapeutika
CN102660511B (zh) * 2012-05-17 2013-08-21 肇庆大华农生物药品有限公司 一种降低血清中胰酶抑制物的方法及其应用
SG11201507454XA (en) * 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
EP3063273B8 (de) 2013-10-28 2020-12-30 Blue Sky Vaccines GmbH Influenza-virus-vektor für virentherapie
MA41506A (fr) * 2015-02-13 2017-12-19 Takeda Vaccines Inc Procédés de production de virus pour produire des vaccins
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
WO2018183429A1 (en) * 2017-03-30 2018-10-04 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
US11629338B2 (en) 2017-11-09 2023-04-18 Jianshun Biosciences Co., Ltd. Method for acclimating and suspending Vero and second order production process for virus
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung

Also Published As

Publication number Publication date
WO2002024876A2 (en) 2002-03-28
CA2423038A1 (en) 2002-03-28
JP2004509903A (ja) 2004-04-02
AU2002223560B2 (en) 2006-06-29
AU2356002A (en) 2002-04-02
EP1358319A2 (de) 2003-11-05
US20040137013A1 (en) 2004-07-15
EP1358319B1 (de) 2009-06-17
US7494659B2 (en) 2009-02-24
DK1358319T3 (da) 2009-10-05
CN1582333A (zh) 2005-02-16
DE60139026D1 (de) 2009-07-30
CN1582333B (zh) 2010-06-16
JP5063852B2 (ja) 2012-10-31
CA2423038C (en) 2012-03-13
KR20030061810A (ko) 2003-07-22
ES2327103T3 (es) 2009-10-26
KR20080043891A (ko) 2008-05-19
WO2002024876A3 (en) 2003-08-28
KR100927517B1 (ko) 2009-11-17

Similar Documents

Publication Publication Date Title
ATE434035T1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
ATE429246T1 (de) Verfahren zur herstellung von biologischen produkten in protein-freiem kultur
HRP20120790T1 (hr) Cjepiva protiv influence sa niskom koliäśinom aditiva
BRPI0518568A2 (pt) mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
DK1618889T3 (da) Influenzavaccine
ATE286537T1 (de) Vakzinproduktion
EP1504112A4 (de) Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
AR011216A1 (es) Una vacuna a base de antigenos superficiales contra la gripe, un metodo para prepararla y un metodo para la preparacion de proteinas antigenicas superficiales a partir de virus de gripe propagados sobre un cultivo celular animal
ATE469972T1 (de) Multiplasmid-system zur erzeugung des grippevirus
PL1951296T3 (pl) Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem
DE3480005D1 (en) Novel viruses and vaccines
MX2010003202A (es) Metodo para producir virus de la gripe.
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
DE60311990D1 (de) Verfahren zur herstellung eines virus inaktivierten thrombin präparates
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
NO20020615L (no) Vaksine
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
DK1802746T3 (da) Virosompartikler indeholdende antigener fra influenzavirus og hepatitis B-virus
JP6708636B2 (ja) Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
PE20212213A1 (es) Cepas de vbi y usos de las mismas
TH60798A (th) ชีวมวลที่เป็นอนุภาคเอมบริโอของสัตว์ปีกสำหรับการผลิตแอนติเจนของไวรัส

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1358319

Country of ref document: EP